Sinus Bradycardia Associated With Daclizumab in Liver Transplant Recipients: Report of 3 Cases

Simple item page
dc.contributor.authorBassily-Marcus, Adel
dc.contributor.authorBenjamin, Ernest
dc.contributor.authorManasia, Anthony
dc.contributor.authorOropello, John
dc.contributor.authorMurgolo, Victor
dc.contributor.authorLeibowitz, Andrew
dc.contributor.authorKohli-Seth, Roopa
dc.date.accessioned2025-11-19T12:05:35Z
dc.date.issued2008-12
dc.description.abstractDaclizumab is a commonly used immuno­sup­pressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of brady­cardia following its administration in orthotopic liver transplant.
dc.identifier.citationExperimental and Clinical Transplantation, Cilt 6, Sayı 1, 2008, ss. 80-83en
dc.identifier.eissn2146-8427en
dc.identifier.issn1304-0855
dc.identifier.issue1en
dc.identifier.urihttps://hdl.handle.net/11727/13922
dc.identifier.volume6en
dc.language.isoen_US
dc.publisherBaşkent Üniversitesi
dc.sourceExperimental and Clinical Transplantationen
dc.subjectBradyarrhythmias
dc.subjectZenapax
dc.subjectDrug-induced
dc.subjectFamotidine
dc.subjectTransplantation
dc.titleSinus Bradycardia Associated With Daclizumab in Liver Transplant Recipients: Report of 3 Cases
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
80.pdf
Size:
130.73 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Başkent Üniversitesi Makaleler